Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
Phase 1
Terminated
- Conditions
- Lymphoma
- Registration Number
- NCT00460460
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
- Patients with AML, a certain type of ALL, NHL and MM
- certain types of cancer of the lymph nodes
- certain types of leukemias (blood cancers)
- disease has or will fail with other treatments
- relatively good overall health other than your cancer
Read More
Exclusion Criteria
- poor bone marrow function (not producing enough blood cells)
- serious heart conditions
- poor liver or kidney function
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Research site
🇺🇸Buffalo, New York, United States
Research Site
🇨🇦Toronto, Ontario, Canada